EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research and innovation programmes with the goal of creating and funding collaborative research and innovation projects that can convert research in nanotechnology into practical gains in medicine.
Under the umbrella of EuroNanoMed III, the 12th Joint Transnational Call is launched for funding multilateral innovative research projects on nanomedicine.
EuroNanoMed aims (i) to support translational research projects that combine innovative approaches in the field of nanomedicine and (ii) to encourage and enable transnational collaboration between public and private research groups from academia, clinical/public health research or research teams from industrial enterprises (all size). The participation of Medical Doctors and SMEs will be strongly encouraged.
For more information see the Call text.
Project proposals will address multidisciplinary and translational research. Project proposals will need to cover at least one of the following areas that are equal in relevance for this call:
At the end, projects should fall within, but are not limited to, Technology Readiness Levels (TRL)[1] 3-6, although for being realistic and coherent with the characteristics of the call, projects should propose advancements for a maximum of two TRL levels during their lifetime.
[1] Horizon 2020 scale for TRL: https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-g-trl_en.pdf
For more information see the Call text.
A consortium applying to this call will be required to include research group(s) from at least 2 of the 3 following categories, if eligible according to relevant national/regional funding organisations’ regulations for research funding[1]:
Only transnational projects will be funded. Each consortium submitting a proposal will need to involve a minimum of 3 eligible and a maximum of 5 eligible partners from at least 3 different countries participating to the call (see list below) though no more than 2 eligible partners from the same country participating in the call will be accepted in one consortium.
Partners not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding organisation) may participate in transnational projects if they are able to secure their own funding. However, no more than one research group with own funding can be included in a consortium. The coordinator must be eligible to be funded by the participating funding organisations.
The maximum number of partners will possibly be increased from 5 to 7 (including eligible for funding and non-eligible for funding research groups) if partners from these participating countries, whose scientific community has been under-represented in past EuroNanoMed calls: Bulgaria, Czech Republic, Egypt, Estonia, Latvia, Lithuania, Romania, Slovakia, Taiwan and Turkey:
Number of partners requesting funding (eligible partners) | 3 | 4 | 5 | 6
(only with at least one underrepresented) |
7
(only with at least 2 underrepresented) |
Possible number of additional partners with own funding | 1 | 1 | 1 | 1 | 0 |
Please note! Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EuroNanoMed funding organisation respective of the country/region from which applicants have applied. The applications are therefore subject to eligibility criteria of individual funding organisations.
Applicants are strongly advised to contact their relevant funding organisation contact person before submitting an application; please note that for some countries/regions it might be mandatory.
For more information see the Call text.
Have a look at the European Nanomedicine Map: https://etp-nanomedicine.eu/about-nanomedicine/european-nanomedicine-map/
And use the EuroNanoMed partnering tool: https://www.euronanomed.net/partner-search/list-of-searches-and-offers/
Or use any other H2020 NCP Partner-Search Tools here.
Belgium, Bulgaria, Czech Republic, Egypt, Estonia, France, Israel, Italy, Latvia, Lithuania, Poland, Romania, Slovakia, Spain, Taiwan and Turkey.
Research project consortia who intend to submit a transnational proposal should register at https://ptoutline.eu/app/euronanomed2021, clicking the “to register” button and following the directions. Electronic proposal submission of proposals on the indicated website is mandatory.
JCS is hosted by the National Institute of Health Carlos III
Monforte de Lemos, 5 28029 Madrid, Spain
Contact person for the Joint Call Secretariat: Astrid Valencia Quiñónez
Email: ma.valencia@isciii.es
Tel. + 34 91 822 2227
Guidelines for Pre-Clinical Studies
Guidelines for Clinical Studies
Full proposal application form
Country | Funding Organisation | Contact point | |
Belgium | FRS-FNRS | Joël Groeneveld | joel.groeneveld@frs-fnrs.be |
Bulgaria | BNSF | Milena Aleksandrova | aleksandrova@mon.bg |
Czech Republic | TACR | Kristina Nehilčová | kristina.nehilcova@tacr.cz |
Egypt | ASRT | Amr Radwan
Salma Essawi |
radwan.amro@gmail.com |
Estonia | ETAg | Argo Soon | argo.soon@etag.ee |
France | ANR | Martine Batoux | ENMCalls@anr.fr |
Israel | CSO-MOH | Irit Allon
Orly Spivak |
Irit.allon@moh.gov.il |
Italy | IMH | Maria Grazia Mancini | mg.mancini-esterno@sanita.it |
Latvia | VIAA | Linda Vecbiškena | Linda.Vecbiskena@viaa.gov.lv |
Lithuania | RCL | Živilė Ruželė | zivile.ruzele@lmt.lt |
Poland | NCBR | Marcin Chmielewski | Marcin.Chmielewski@ncbr.gov.pl |
Romania | UEFISCDI | Mihaela Manole | mihaela.manole@uefiscdi.ro |
Slovakia | SAS | Katarina BIBOVA | bibova@up.upsav.sk |
Spain | ISCIII | Astrid Valencia | ma.valencia@isciii.es |
Spain | CDTI | Marina Sopeña Escalona | marina.sopena@cdti.es |
Taiwan | MOST | Ching-Mei Tang | cmtom@most.gov.tw |
Turkey | TUBITAK | Dr. Mahmut Özer | mahmut.ozer@tubitak.gov.tr |
Ⓒ All rights reserved EuroNanoMed III, 2018